Evotec SE (EVO) stock
EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
$1.46−0.02 (-1.35%)
Close on Nov 18, 2026Market cap $519.11MP/E –Yield –
Evotec free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was -€81.72M. The highest annual figure on record is €24.46M in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€81.72M | – |
| FY2024 | Dec 31, 2024 | -€99.25M | – |
| FY2023 | Dec 31, 2023 | -€176.88M | -823.2% |
| FY2022 | Dec 31, 2022 | €24.46M | +219.4% |
| FY2021 | Dec 31, 2021 | €7.66M | – |
| FY2020 | Dec 31, 2020 | -€54.35M | -598.9% |
| FY2019 | Dec 31, 2019 | €10.89M | – |
See a number that looks wrong?